Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors

Clinical Breast Cancer

Volumn 8, Issue SUPPL. 1, 2007, Pages

  Brufsky, Adam M ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Anastrozole; Bisphosphonates; Bone mineral density; Exemestane; Letrozole

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; ANTIEMETIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; EXEMESTANE; GOSERELIN; IBANDRONIC ACID; LETROZOLE; PAMIDRONIC ACID; PARACETAMOL; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; TAMOXIFEN CITRATE; TRIPTORELIN; VITAMIN D; ZOLEDRONIC ACID;

ABDOMINAL PAIN; ACUTE PHASE RESPONSE; ARTHRALGIA; BONE DENSITY; BONE METABOLISM; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BREAST CANCER; CANCER STAGING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DENTAL CARE; DIET; DUAL ENERGY X RAY ABSORPTIOMETRY; EDEMA; ENZYME INHIBITION; EXERCISE; FATIGUE; FEVER; FLU LIKE SYNDROME; FRACTURE; FRAGILITY FRACTURE; GASTRITIS; GASTROINTESTINAL TOXICITY; HIP FRACTURE; HOT FLUSH; HUMAN; KIDNEY DYSFUNCTION; MENOPAUSE; MONOTHERAPY; MYALGIA; NAUSEA; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SIDE EFFECT; TOOTH INJURY; VOMITING; WOMEN'S HEALTH;

EID: 38849192612     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2007.s.009     Document Type: Article

References (74)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106-30.
2. Gonnelli S, Cadirni A, Caffarelli C, et al. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone 2007; 40:205-10.
3. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23:619-29.
4. Coates AS, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25:486-92.
5. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369:559-70.
6. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365:60-2.
7. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366:455-62.
8. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97:1262-71.
9. The NCCN Breast Cancer Clinical Practice Guidelines in Oncology (Version 1.2007).© 2006 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed: January 5, 2007.
10. Venturini M, Del Mastro L. Safety of adjuvant aromatase inhibitor therapy. Cancer Treat Rev 2006; 32:548-56.
11. ClinicalTrials.gov [Web site]. Available at: http://www.cancer.gov/ clinicaltrials.gov. Accessed: December 28, 2006.
12. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid effectively prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2006; 25:820-8.
13. Heshmati HM, Khosla S, Robins SP, et al. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res 2002; 17:172-8.
14. Chien AJ, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol 2006; 24:5305-12.
15. Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary beast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006; 24:3629-35.
16. Bundred N, Campbell I, Coleman R, et al. Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZO-FAST Trial). Presented at: the 5th European Breast Cancer Conference; March 21-25, 2006; Nice, France. Abstract 12.
17. Brufsky A, Lund K, Cobb P, et al. Twenty-four month follow-up of the effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Presented at: 29th San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, TX. Abstract 5060.
18. Brufsky A, Bundred N, Coleman R, et al. An integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Presented at: 29th San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, TX. Abstract 107.
19. Coleman RE, Banks LM, Hall E, et al. Intergroup Exemestane Study: 1 year results of the bone sub-protocol. Presented at: 27th San Antonio Breast Cancer Symposium; December 10, 2004; San Antonio, TX. Abstract 401.
20. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007; 8:119-27.
21. Coleman RE on behalf of the ATAC Trialists' Group. Effect of anastrozole on bone mineral density: 5-year results from the 'Arimidex', Tamoxifen, Alone or in Combination. J Clin Oncol 2006; 24(18 suppl):5s. Abstract 511.
22. Geisler J, Lønning PE, Krag LE, et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer 2006; 42:2968-75.
23. Asmar L, Negron AG, Stokoe CT, et al. The effect of tamoxifen or exemestane on bone mineral density after 2 years of adjuvant treatment of postmenopausal women with early breast cancer. Presented at: 29th San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, TX. Abstract 2102.
24. Michaud LB, Goodin S. Cancer-treatment-induced bone loss, part 1. Am J Health Syst Pharm 2006; 63:419-30.
25. Sambrook P, Cooper C. Osteoporosis. Lancet 2006; 367:2010-8.
26. Ramaswamy B, Shapiro CL. Osteopenia and osteoporosis in women with breast cancer. Semin Oncol 2003; 30:763-75.
27. Riggs BL, Khosla S, Melton LJ III. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002; 23:279-302.
28. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359:1929-36.
29. Benito M, Gomberg B, Wehrli FW, et al. Deterioration of trabecular architecture in hypogonadal men. J Clin Endocrinol Metab 2003; 88:1497-502.
30. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA 2002; 288:1889-97.
31. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843:1-129.
32. Perez EA, Weilbaecher K. Aromatase inhibitors and bone loss. Oncology (Williston Park) 2006; 20:1029-48.
33. Marcus R, Holloway L, Wells B, et al. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J Bone Miner Res 1999; 14:1583-95.
34. Chlebowski RT. Bone health in women with early-stage breast cancer. Clin Breast Cancer 2005; 5(suppl 2):S35-S40.
35. Mincey BA, Duh MS, Thomas SK, et al. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer 2006; 7:127-32.
36. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2006; 25:829-36.
37. Eastell R, Hannon RA, Cuzick J, et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006; 21:1215-23.
38. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349:1793-802.
39. Subar M, Goss PE, Thomsen T, et al. Effects of steroidal and nonsteroidal aromatase inhibitors (AIs) on markers of bone turnover and lipid metabolism in healthy volunteers. Proc Am Soc Clin Oncol 2004; 22(14 suppl):734. Abstract 8038.
40. Faulkner KG. Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res 2000; 15:183-7.
41. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21:4042-57.
42. Maxwell C, Viale PH. Cancer treatment-induced bone loss in patients with breast and prostate cancer. Oncol Nurs Forum 2005; 32:589-603.
43. Michaud LB, Goodin S. Cancer-treatment-induced bone loss, part 2. Am J Health Syst Pharm 2006; 63:534-46.
44. Wallace BA, Cumming RG. Systematic review of randomized trials of the effect of exercise on bone mass in pre- and postmenopausal women. Calcif Tissue Int 2000; 67:10-8.
45. Feskanich D, Willett W, Colditz G. Walking and leisure-time activity and risk of hip fracture in postmenopausal women. JAMA 2002; 288:2300-6.
46. Van Poznak C, Sauter NP. Clinical management of osteoporosis in women with a history of breast carcinoma. Cancer 2005; 104:443-56.
47. Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337:670-6.
48. Dawson-Hughes B, Bonner FJ Jr, Gold DT, et al. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Available at: http://www.nof.org/physguide/inside_cover.htm. Accessed: December 10, 2006.
49. Bischoff-Ferrari HA. The 25-hydroxyvitamin D threshold for better health. J Steroid Biochem Mol Biol 2007; 103:614-9.
50. Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007; 85:1586-91.
51. Zinaman RS, Van Poznak CH, Goldberg LM, et al. Supplemental calcium and vitamin D intake of women with early stage breast cancer. Presented at: 27th San Antonio Breast Cancer Symposium; December 8-11, 2004; San Antonio, TX. Abstract 4006.
52. Wang-Gillam A, Miles DA, Hutchins LF. Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonate therapy. Presented at: 29th San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, TX. Abstract 6098.
53. Skelid [package insert]. Bridgewater, NJ: sanofi-aventis U.S. LLC; 2006.
54. Fosamax [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2006.
55. Zometa [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2005.
56. Actonel [package insert]. Cincinnati, OH: Procter & Gamble Pharmaceuticals, Inc; 2006.
57. Aredia [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2006.
58. Boniva [package insert]. Nutley, NJ: Roche Pharmaceuticals; 2006.
59. Delmas PD, Balena R, Confravreux E, et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997; 15:955-62.
60. Waltman NL, Twiss JJ, Ott CD, et al. Testing an intervention for preventing osteoporosis in postmenopausal breast cancer survivors. J Nurs Scholarsh 2003; 35:333-8.
61. Sambrook PN, Geusens P, Ribot C, et al. Alendronate produces greater effects than raloxifene on bone density and bone turn-over in postmenopausal women with low bone density: results of EFFECT (Efficacy of Fosamax® Versus Evista® Comparison Trial) International. J Intern Med 2004; 255:503-11.
62. McClung MR, Wasnich RD, Hosking DJ, et al. Prevention of post-menopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study. J Clin Endocrinol Metab 2004; 89:4879-85.
63. Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005; 20:141-51.
64. Van Poznak C, Hannon RA, Clack G, et al. The SABRE study: effects of risedronate on bone mineral density and bone metabolism in post-menopausal women using anastrozole as adjuvant therapy for hormone receptor-positive early breast cancer - first results. Presented at: 29th San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, TX. Abstract 4061.
65. ClinicalTrials.gov [Web site]. Available at: http://www.clinicaltrials. gov. Accessed: December 28, 2006.
66. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006; 17:897-907.
67. Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 2005; 10:52-62.
68. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98:1735-44.
69. Ruggiero S, Gralow J, Marx RE, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2006; 2:7-14.
70. Whannel KJ, McLellan A, Wilson CR, et al. The need for DXA assessment of breast cancer patients following 5 years of tamoxifen prior to starting an aromatase inhibitor. Presented at: 29th San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, TX. Abstract 4046.
71. Epstein S. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther 2006; 28:151-73.
72. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350:1189-99.
73. Baum M, Buzdar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359:2131-9.
74. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in post-menopausal women with primary breast cancer. N Engl J Med 2004; 350:1081-92.